

13 August 2026

Ranibizumab Usage in Belfast Trust

I would like to know the percentage breakdown of all Ranibizumab usage within Belfast Trust. In particular, I would like the percentage of usage that is attributable to Ongavia v Lucentis.

If possible, please also provide the total amount of Biosimilar Ranibizumab used in a recent financial year, along with the same data split by these two brands.

The table below summarises the issue of Ranibizumab to Belfast Trust wards / clinics / departments for the financial year 2025 / 2026.

Product Description	Sum of Quantity as vials / syringe	% of usage
Byooviz 2.3mg/0.23ml Solution for Injection Vial	37	4%
Lucentis 1.65mg/0.165ml Solution for Injection Pre-Filled Syringe	814	94%
Lucentis 2.3mg/0.23ml Solution for Injection Vial	20	2%
Grand Total	871	100%

Belfast Trust records indicate no usage of Ongavia biosimilar within the scope of this request.